Menopause in a man’s world: healthcare and research disparities based on gender and race
By Rosie Wagener
Menopause seems like a distant, dreaded inevitability for most young women like myself. However, it consumes the lives of many older women; some with symptoms that seriously impact their quality of life. Hormone replacement therapy (HRT) alleviates the symptoms of menopause by replacing hormones, e.g. oestrogen and progesterone. Recently, HRT prescriptions have increased, but this change isn’t uniform. A recent Oxford study has shown that women from Black African backgrounds are six times less likely to receive HRT than their white counterparts, revealing stark racial and socioeconomic gaps in access to UK healthcare, stemming from a history of dismissing the need for both female and ethnic representation in medical research.
Women have long been underrepresented in research. A review in The Lancet journal estimates that only 39% of trials included equal numbers of women and men. Male subjects permeate almost all study areas, even for conditions that predominantly affect women. For example, flibanerin (the ‘female Viagra’) was almost exclusively tested on male animals during preclinical trials. This perpetuates the outdated assumption, made mostly out of ignorance, that female bodies and hormones function almost identically to those of a privileged male – an incredibly dangerous bias that leads to misdiagnosis and gaps in care. Many purely women’s conditions, such as the effects of menopause, are not fully covered in clinical training. This gap in education is the first pitfall contributing to inequalities in HRT prescription. A 2018 survey of healthcare professionals published in the British Journal of Family Medicine revealed only half of the clinicians in the UK had received any specific menopause training. It is fair to say that informative details about menopause won’t get spread widely enough if the menopause education for healthcare professionals themselves is not as universal as it can be, as is the case with many conditions affecting women that require the self-reporting of symptoms.
When healthcare workers cannot provide extensive information about menopause, women seek understanding from elsewhere. The European Menopause Survey demonstrated that women mainly obtained this information from the media. This unregulated information runs the risk of being scientifically inaccurate, contributing to situations of increased anxiety around seeking help.
A recent Oxford study has shown that women from Black African backgrounds are six times less likely to receive HRT than their white counterparts
This information gap is especially highlighted in areas with strong populations of ethnic minority women. One method to reduce the gap is cultural competence training – many would argue, including myself, that this is integral to allowing NHS professionals to provide properly relevant information and advice, specific to each patient. After all, healthcare professionals are better served if they are cognisant of how cultural differences may influence a patient’s understanding of their situation. Without it, GPs may overlook signs of menopause that do not fit the pattern they were taught. The Study of Women’s Health Across the Nation in the US reported that menopause in Black women occurred eight months earlier than in white women, meaning an early presentation of symptoms may be more readily dismissed by a clinician unaware of the difference. The variation in ways in which women communicate their symptoms is a huge determining factor in receiving a correct referral for further treatment. The British Journal of General Practice detailed how Black women often felt unseen in medical settings, illustrating how a lack of representation in informative leaflets and posters produced the sense that menopause and other women’s healthcare treatments were only being designed around white women.

Tackling inequalities in women’s health was made a key priority by the government last year, with the commissioning of Women’s Health Hubs to increase the accessibility of healthcare for menopause and menstruation. NHS England set guidance in 2024/25 that there should be a Health Hub in every region, and as of September 2024, 36 out of 42 regional Integrated Care Boards in the UK reported having an open women’s health hub. The NHS should absolutely be highlighting specific regions and deprived areas in which healthcare inequality is prevalent and ensure the hubs here are specialised in menopause treatment to truly address this gap in HRT prescription. We can only hope that these inequalities are addressed in the next 25 years, so that our generation does not face these same challenges.
Image: Morena Rossi via Wikimedia Commons

